Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-01

Study Completion Date

2028-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this observational study is to examine real-world clinical practice regarding the use of vasopressin as a second-line vasopressor in adult patients admitted to Intensive Care Units (ICUs) with septic shock.

The study focuses on critically ill adults (≥18 years) diagnosed with septic shock and treated with norepinephrine and vasopressin.

The main research questions are:

* Does early initiation of vasopressin-defined by the norepinephrine dose at the time of introduction-reduce mortality in patients with septic shock?
* What is the impact of vasopressin as a second vasopressor on renal function and the progression of organ dysfunction in septic shock patients?

Participants will:

* Be admitted to an ICU with a diagnosis of septic shock.
* Receive vasopressin as an adjunct to norepinephrine for hemodynamic support.
* Be monitored daily throughout their ICU stay, with data collected through a dedicated REDCap system.
* Have relevant clinical data pseudonymized and incorporated into the study database for statistical analysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Systematic Adjunction of Vasopressine in Septic Shock

NCT07052084

Septic Shock

NOT_YET_RECRUITING PHASE3

Effect of Vasopressin on Kidney and Cardiac Function in Septic Shock

NCT06125184

Kidney Injury, Acute Cardiac Function Failed

RECRUITING NA

Renal Outcomes in the Early Use of Vasopressin in the Treatment of Septic Shock

NCT06471231

Septic Shock Renal Function Replacement

RECRUITING PHASE4

Hypotension in the Weaning From Vasopressor Drugs

NCT05506319

Septic Shock

COMPLETED PHASE4

Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator

NCT06426407

Shock, Septic

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Usage of vasopressin (VAP) as a second-line vasopressor in septic shock patients.

A state-of-the-art line of research in septic shock management focuses on the potential use of a second vasopressor agent. Current efforts aim to determine which drug should be used and the optimal timing for its initiation. In line with this, the Surviving Sepsis Campaign 2021 clinical guide recommends considering vasopressin-arginine (VAP) as a second-line vasopressor when norepinephrine (NAD) doses exceed 0.25 µg/kg/min, although this suggestion is based on limited evidence and remains weak.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ICU admission with a septic shock diagnosis.
* Age 18 years or above at ICU admission.
* Use of vasopressin as an adjunct of norepinephrine.

For the purposes of this study, septic shock is defined by full compliance with the following criteria.

* Sustained arterial hypotension or serum lactate above 2 mmol/L.
* Adequate but unsuccessful fluid resuscitation.
* Vasopressor usage to maintain a mean arterial pressure above 65 mmHg.
* Probable or proven infectious etiology.

Patients with some of the following conditions will be automatically excluded.

* Pregnancy.
* Ischemic cardiogenic shock.
* Acute intestinal ischemia.
* Readmission to the Intensive Care Unit.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No